SCHEDULE: NEA Funds Disclose 22.2% Stake in SpyGlass Pharma Post-IPO

New Enterprise Associates funds and their managers have filed a Schedule 13D, revealing a significant 22.2% beneficial ownership in SpyGlass Pharma, Inc. following its recent IPO.

Summary

• New Enterprise Associates (NEA) funds, specifically NEA 16 and NEA 17, along with their general partners and individual managers, collectively reported beneficial ownership of SpyGlass Pharma, Inc. common stock.
• The aggregate beneficial ownership for most reporting persons is 7,392,301 shares, representing 22.2% of the outstanding common stock.
• Ali Behbahani, an individual manager, beneficially owns 7,393,823 shares (22.2%), including options to purchase 1,522 shares exercisable within 60 days.
• Edward T. Mathers and Rick Yang, also individual managers, beneficially own 6,035,038 shares, representing 18.1% of the class.
• The ownership stems from prior private investments in preferred stock and a purchase of 937,500 common shares at the IPO price of $16.00 per share by NEA 17.
• A one-to-5.7329 reverse stock split was effected on January 28, 2026, prior to the preferred stock converting to common stock.
• The funds acquired the shares for investment purposes and may adjust their holdings based on market conditions and the Issuer's prospects.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, primarily due to the significant and continued investment by a reputable venture capital firm, New Enterprise Associates, in SpyGlass Pharma post-IPO. This signals institutional confidence and provides clarity on a major shareholder's position and rights.

Positives

• Significant investment by a prominent venture capital firm (New Enterprise Associates) indicates confidence in SpyGlass Pharma, Inc.
• The reporting persons hold substantial registration rights, including demand and "piggyback" rights, which could facilitate future liquidity for investors.
• The Issuer is responsible for most registration expenses, reducing potential costs for the reporting persons if they choose to sell shares.

Risks

• The reporting persons may dispose of or acquire additional shares of the Issuer depending on market conditions, their evaluation of the business, and other factors, which could impact share price volatility.
• A lock-up agreement and market standoff agreement restrict the sale or transfer of shares by the Funds for 180 days after February 5, 2026, potentially limiting liquidity for these large shareholders in the short term.

Future Outlook

The reporting persons acquired the shares for investment purposes and may, depending on market conditions, their continuing evaluation of the Issuer's business and prospects, and other factors, dispose of or acquire additional shares of the Issuer. No present plans exist for extraordinary corporate transactions, changes in management or board, capitalization, or corporate structure.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing highlights a significant post-IPO stake by New Enterprise Associates, a prominent venture capital firm, in SpyGlass Pharma, Inc. This indicates continued institutional support for the newly public pharmaceutical company, a common occurrence as VC firms transition their private investments into public market holdings. The disclosure of substantial ownership by a well-known VC firm can often be viewed positively by the market, signaling validation of the company's potential within the competitive biotech and pharma landscape.

Comparison to Industry Standards

• StockSavvy.ai observes that the beneficial ownership of 22.2% by New Enterprise Associates is a substantial stake for a venture capital firm post-IPO, aligning with typical patterns where early-stage investors maintain significant positions to realize long-term value.
• For example, similar to how Flagship Pioneering often retains large stakes in its incubated biotech companies like Moderna (MRNA) or Denali Therapeutics (DNLI) after their public debuts, NEA's continued large holding in SpyGlass Pharma suggests a long-term investment horizon.
• The inclusion of demand and 'piggyback' registration rights in the Investors' Rights Agreement is standard practice for major institutional investors, providing mechanisms for future liquidity while the lock-up and market standoff agreements are typical for IPOs to ensure market stability post-listing.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a major institutional investor's significant stake, which can influence market perception and potentially provide a floor for the stock price due to the lock-up period. Future sales by NEA could impact share price.
• Management: The presence of a large, active institutional investor like NEA can imply a level of oversight and strategic input, though no specific board seats or management influence are detailed in this filing.

Next Steps

• The lock-up and market standoff agreements will expire approximately 180 days after February 5, 2026, after which the reporting persons will have greater flexibility to sell shares.
• The reporting persons may acquire or dispose of additional shares of SpyGlass Pharma, Inc. in the future based on market conditions and their evaluation of the company.
• The reporting persons may exercise their demand or "piggyback" registration rights to facilitate the sale of their shares, subject to certain conditions and limitations.

Key Dates

Recommendation

The filing is a beneficial ownership disclosure (Schedule 13D) by a major venture capital firm, New Enterprise Associates, post-IPO. It primarily provides transparency on their significant stake and associated rights and restrictions. While the substantial investment by NEA is a positive signal of institutional confidence in SpyGlass Pharma, the filing does not contain new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The lock-up period also limits immediate liquidity for these large holders. Therefore, a 'hold' recommendation is appropriate as investors await further operational updates from SpyGlass Pharma.

Keywords

SpyGlass Pharma, New Enterprise Associates, NEA, Schedule 13D, beneficial ownership, common stock, IPO, venture capital, biotech, pharmaceutical, investment, registration rights, lock-up